Cervical myelopathy

Introduction and Overview

Cervical myelopathy (CM) is a clinical syndrome resulting from compression of the cervical spinal cord, leading to progressive neurological dysfunction affecting motor, sensory, and autonomic function. It is the most common cause of non-traumatic spinal cord dysfunction in adults worldwide and is a leading cause of disability in those over 55 years of age.

The most common aetiology is degenerative cervical myelopathy (DCM), which encompasses disc herniation, cervical spondylosis, ossification of the posterior longitudinal ligament (OPLL), and ligamentum flavum hypertrophy. These degenerative changes progressively narrow the cervical spinal canal and compress the spinal cord, resulting in ischaemia, inflammation, and neuronal death.

Cervical myelopathy is often insidious in onset and underdiagnosed in primary care. It should be suspected in any patient over 50 presenting with gait disturbance, hand clumsiness, upper limb weakness, or lower limb spasticity. Prompt recognition and specialist referral is critical — surgical decompression is the only effective intervention to halt progression, and delay worsens outcomes. This guideline focuses on the GP’s role in recognition, investigation, and timely referral.

Pathophysiology

The cervical spinal cord occupies approximately 70% of the spinal canal at rest. Degenerative changes — disc protrusion, osteophyte formation, facet joint hypertrophy, and ligamentum flavum buckling — progressively reduce available space, compressing the cord both statically and dynamically during neck flexion and extension.

Mechanical compression causes direct axonal injury, demyelination, and grey matter neuronal loss. Superimposed vascular compromise — compression of the anterior spinal artery or its feeding radiculomedullary vessels — exacerbates ischaemic injury. Chronic repetitive microtrauma during cervical movement accelerates cord damage.

Pathologically, the earliest changes occur in the lateral corticospinal tracts (spasticity, upper motor neurone signs in the lower limbs) and the posterior columns (proprioceptive loss, gait ataxia). The anterior horns are affected later, causing lower motor neurone weakness and wasting in the upper limbs at the level of compression. This produces the characteristic mixed UMN/LMN picture of cervical myelopathy.

Congenital cervical canal stenosis (canal diameter <13 mm) is a significant predisposing factor — even mild spondylotic changes may precipitate myelopathy in a congenitally narrow canal. OPLL, more prevalent in East Asian populations, causes progressive anterior cord compression from calcified ligament.

Clinical Presentation

Cervical myelopathy presents insidiously and is frequently missed at first presentation. Neck pain is not a universal feature. The GP must maintain a high index of suspicion in patients over 50 with any combination of the following features.

⚠ Red flags requiring urgent neurosurgical or spinal surgery referral: acute onset or rapid deterioration of myelopathic symptoms; loss of bladder or bowel function; severe bilateral upper or lower limb weakness; following cervical trauma in a patient with known cervical stenosis.

Upper limb symptoms

Hand clumsiness (difficulty buttoning clothes, writing, using cutlery); fine motor impairment; numbness and tingling in hands; grip weakness; wasting of intrinsic hand muscles (interossei, thenar) — LMN signs at level of compression.

Lower limb symptoms

Gait disturbance — wide-based, spastic, or ataxic gait; leg stiffness or heaviness; balance difficulties; tendency to fall; Lhermitte’s sign (electric shock sensation down spine on neck flexion).

Upper motor neurone signs

Lower limb hyperreflexia; extensor plantar responses (Babinski sign); clonus; spasticity; Hoffman’s sign (UMN in upper limb — flick middle finger, watch thumb flex); crossed adductor reflex.

Bladder/bowel

Urinary urgency, frequency, retention, or incontinence in advanced disease. Bowel dysfunction less common but may occur.

Cervical symptoms

Neck pain and stiffness may or may not be present. Radicular arm pain if concurrent nerve root compression (myeloradiculopathy). Symptoms often exacerbated by neck extension.

Key clinical tests in general practice: Hoffman’s sign (sensitivity 58%, specificity 78% for CM); tandem gait test (inability to tandem walk suggests myelopathy); grip-and-release test (<20 repetitions in 10 seconds is abnormal); 30-metre walk test.

Investigations

Investigation of suspected cervical myelopathy is directed at confirming the diagnosis, identifying the level and severity of cord compression, and excluding non-degenerative causes (malignancy, infection, inflammatory, vascular).

MRI cervical spine is the investigation of choice. It is the single most important investigation in suspected CM and should be arranged urgently if clinical features are present. Do not delay specialist referral waiting for MRI results if symptoms are progressing rapidly.

MRI cervical spine

First-line investigation. Demonstrates degree of cord compression, T2 signal change within cord (indicates irreversible injury), level(s) of disease, and disc/ligamentous/bony contributors. Predicts surgical outcome.

CT cervical spine

Superior to MRI for bony detail and OPLL assessment. Used pre-operatively and when MRI is contraindicated (pacemaker, severe claustrophobia). CT myelography if both MRI and CT inadequate.

Plain X-ray

Demonstrates disc space narrowing, osteophytes, instability (dynamic flexion/extension views), canal diameter (Pavlov ratio). Insufficient to diagnose CM — do not use as the primary investigation when myelopathy is suspected.

Bloods

FBC, ESR, CRP, vitamin B12 (peripheral neuropathy/subacute combined degeneration differential), HbA1c (diabetic peripheral neuropathy), VDRL (tabes dorsalis), TFTs, ANA (connective tissue disease myelopathy).

EMG/NCS

Useful to distinguish peripheral neuropathy from myelopathy, and to characterise LMN involvement at the level of compression. Not routinely required for primary diagnosis but may assist in complex cases.

Severity Assessment

Severity grading in cervical myelopathy is used to guide surgical decision-making and track progression. The modified Japanese Orthopaedic Association (mJOA) scale is the most widely used validated tool in clinical practice.

Mild (mJOA 15–17)

Minor hand clumsiness or gait disturbance; independent function maintained; no bladder/bowel dysfunction. Surgical decision individualised — close monitoring with low threshold for surgery if any progression. Neurosurgical or spinal surgery referral for assessment.

Moderate (mJOA 12–14)

Significant upper and/or lower limb dysfunction; gait abnormality; possible bladder symptoms; some independence preserved. Surgical decompression strongly recommended — highest potential for functional improvement. Urgent specialist referral.

Severe (mJOA <12)

Significant disability; dependent for ADLs; bladder/bowel dysfunction. Urgent surgical decompression — prevents further deterioration though recovery incomplete. Immediate neurosurgical referral. Surgical risk-benefit discussion with patient and family.

The Nurick grade and NDI (Neck Disability Index) are also used. In general practice, the GP’s role is clinical recognition and urgent referral — formal severity grading is performed by the specialist.

General Treatment Principles

Surgical decompression is the definitive treatment for cervical myelopathy of moderate-to-severe severity. Conservative management alone does not halt disease progression and is associated with high rates of neurological deterioration. The GP’s primary role is recognition and timely specialist referral.

Key principle: Cervical myelopathy is a progressive condition. Early surgical decompression, before significant cord signal change on MRI, is associated with significantly better neurological outcomes. Delayed referral results in irreversible spinal cord injury.

Surgical decompression: Indicated for moderate-to-severe CM or any mild CM showing progression. Approaches include anterior cervical discectomy and fusion (ACDF), posterior laminectomy/laminoplasty, or combined approaches, selected based on pathology and surgical expertise. Surgery halts progression and may improve function.
Conservative management (mild, non-progressive CM only): Considered only for truly mild, stable myelopathy in patients with high surgical risk or patient preference after detailed discussion. Requires close neurological monitoring every 3–6 months. Any progression mandates surgical reassessment.
Activity modification: Avoid contact sports, trampolining, and high-risk activities for falls. Avoid extreme cervical flexion and extension. Fall prevention strategies (home assessment, walking aids, physiotherapy).
Analgesia: For associated neck pain or radiculopathy — paracetamol or NSAIDs short-term. Opioids generally not appropriate as a primary management strategy given surgical nature of disease.
Physiotherapy: Post-operative rehabilitation; balance and gait training; upper limb fine motor exercises. Pre-operatively, avoid aggressive cervical manipulation.

Directed Pharmacotherapy

Pharmacotherapy in cervical myelopathy is directed at symptomatic management of associated pain, spasticity, and neuropathic symptoms. There is no pharmacological treatment that modifies the underlying cord compression or halts myelopathic progression.

Important: Pharmacotherapy is adjunctive only. Surgical decompression is the only treatment that changes the natural history of CM. Delay in referral for appropriate treatment while managing symptoms pharmacologically risks irreversible neurological deterioration.

💊

Paracetamol

Panadol® and generics | Neck pain or radicular pain associated with CM

DOSE 500–1000 mg orally every 4–6 hours as needed; maximum 4 g/day

PBS STATUS ✓ PBS: General benefit

NOTES First-line for associated neck or radicular pain. Does not treat myelopathy. Avoid masking progressive neurological symptoms.

⚠️

Baclofen

Clofen® and generics | Spasticity associated with cervical myelopathy

DOSE 5 mg orally TDS initially; titrate by 5 mg every 3 days to effect; usual dose 30–75 mg/day in divided doses; do not exceed 100 mg/day

PBS STATUS ✓ PBS: Authority required — spasticity due to neurological disease

NOTES GABA-B agonist; reduces spasticity in lower limbs. Titrate slowly to avoid sedation, weakness, and withdrawal seizures on abrupt cessation. Specialist initiation preferred. Do not use as primary treatment to delay surgical referral.

💊

Pregabalin

Lyrica® and generics | Neuropathic pain associated with cervical myeloradiculopathy

DOSE 75 mg orally BD initially; titrate to 150–300 mg BD over 1–2 weeks based on response and tolerability; maximum 600 mg/day

PBS STATUS ✓ PBS: Authority required — neuropathic pain

NOTES Calcium channel alpha-2-delta ligand; reduces neuropathic pain. Sedation, dizziness, weight gain, peripheral oedema common. Dose reduction in renal impairment. Risk of misuse/dependence. Adjunct only — does not treat underlying cord compression.

Acute and Emergency Management

Acute or rapidly deteriorating cervical myelopathy is a neurological emergency requiring same-day emergency referral to neurosurgery or spinal surgery. The GP must be able to recognise this scenario.

⛔ EMERGENCY: Same-day referral or ED presentation if: acute onset bilateral limb weakness or paralysis; acute bladder or bowel retention/incontinence in context of cervical myelopathy; rapid neurological deterioration over hours to days; cervical trauma with myelopathic signs in known stenosis.

Call 000 / direct ED presentation for acute myelopathic deterioration — do not delay for outpatient MRI if clinical picture is deteriorating rapidly.
Cervical immobilisation (semi-rigid collar) if traumatic mechanism — avoid excessive movement pending imaging.
IV methylprednisolone is NOT routinely indicated for degenerative cervical myelopathy (evidence does not support steroid use outside acute traumatic SCI protocols).
Urgent MRI cervical spine if not already done — organise directly via ED or neurosurgery if rapidly deteriorating.
For subacute but clearly progressive myelopathy: expedited neurosurgical/spinal surgery referral within days, not weeks.

Monitoring and Review

Monitoring of cervical myelopathy in primary care is relevant primarily for patients under specialist care awaiting surgery, post-operative patients, or the rare patient managed conservatively. The key monitoring task is detecting neurological deterioration.

Neurological monitoring

Reassess Hoffman’s sign, grip strength, tandem gait, lower limb reflexes, and plantar responses at each visit. Any new or worsening findings require urgent specialist contact.

Functional monitoring

Grip-and-release test (30-second repetitions), 30-metre timed walk, and handwriting assessment provide objective functional markers. Use mJOA score if trained — otherwise refer findings to specialist.

Post-operative

Post-surgical patients require GP follow-up for wound care, medication management, and physiotherapy coordination. Neurological recovery may continue for 12–24 months post-operatively. Report any new neurological symptoms to surgeon.

Conservative management monitoring

Mild stable CM: specialist review every 3–6 months; GP review every 1–3 months to detect progression. Any deterioration triggers urgent re-referral.

Medication review

Baclofen: avoid abrupt cessation (withdrawal seizures); titrate slowly; review spasticity response. Pregabalin: reassess need regularly; monitor for sedation, falls risk, misuse.

Special Populations

Specific population considerations in the management of cervical myelopathy.

Elderly Patients

Higher surgical risk due to comorbidities. Pre-operative cardiac and anaesthetic assessment essential. Surgical benefit persists in older patients — age alone is not a contraindication. Conservative management may be preferred in frail patients with short life expectancy or high operative risk after specialist discussion.

Patients with Rheumatoid Arthritis

Atlantoaxial instability and subaxial subluxation cause myelopathy distinct from degenerative CM. Pre-operative dynamic flexion/extension X-rays or CT mandatory before any anaesthesia. Rheumatologist liaison with spinal surgeon.

OPLL (East Asian populations)

Higher prevalence of OPLL in Japanese, Korean, and Chinese Australians. OPLL causes anterior cord compression from calcified posterior longitudinal ligament. Posterior decompression often preferred over anterior in multilevel OPLL.

Congenital Canal Stenosis

Pavlov ratio <0.8 on lateral X-ray (AP diameter of canal : vertebral body) suggests developmental stenosis. These patients develop myelopathy with minimal degenerative change. Counselling about contact sport risk.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander peoples may face specific barriers to timely diagnosis and treatment of cervical myelopathy, including access to MRI, specialist services, and surgical care.

🌐 Access to Specialist Services

Neurosurgical and spinal surgery services are concentrated in urban centres. Telehealth specialist consultations and patient assistance schemes (e.g., PATS — Patient Assisted Travel Scheme) can facilitate access. ACCHOs can coordinate specialist referrals and transport.

🤝 Culturally Safe Assessment

Gait and balance difficulties in the context of other comorbidities (e.g., diabetes, alcohol-related neuropathy) may confound myelopathy diagnosis. Engage Aboriginal Health Workers for culturally appropriate history-taking and education about the diagnosis and need for urgent specialist review.

🏠 Comorbidity Burden

Higher rates of diabetes and peripheral neuropathy may coexist with cervical myelopathy, complicating both diagnosis (mixed peripheral/central features) and surgical risk assessment. Comprehensive pre-operative medical optimisation is important.

📋 Post-operative Support

Post-operative physiotherapy rehabilitation and follow-up must be planned before surgery, particularly for patients returning to remote communities. Telehealth physiotherapy and community health workers can support post-operative rehabilitation.

Medication Stewardship

Medication stewardship in cervical myelopathy focuses on avoiding harm from pharmacological management and ensuring pharmacotherapy does not substitute for or delay appropriate surgical referral.

Do not use opioids as primary management for cervical myelopathy — they mask progressive neurological symptoms and create dependence without treating the underlying cord compression.
Baclofen stewardship: Do not initiate without specialist input if possible; never cease abruptly (withdrawal seizures); review spasticity regularly and titrate to minimum effective dose.
Pregabalin stewardship: Short-term use for neuropathic pain; reassess at 3–6 months; monitor for dependence and cognitive effects particularly in elderly.
Corticosteroids: Not indicated for degenerative CM; avoid empirical dexamethasone or methylprednisolone in the primary care setting without specialist direction.
NSAIDs: Short-term only for associated neck pain; avoid long-term use given age-related comorbidities in typical CM patients.
Avoid over-reliance on conservative management: Physiotherapy, acupuncture, and manual therapy do not treat cord compression and should not delay surgical assessment.

Follow-up and Referral Pathway

The GP’s key role in the follow-up of cervical myelopathy is ensuring timely specialist engagement, monitoring for neurological deterioration, and coordinating post-operative care.

Suspected CM at Presentation

Arrange urgent MRI cervical spine; refer to neurosurgery or spinal surgery (urgency guided by severity and rate of progression); if rapid deterioration — ED or same-day specialist contact.

Awaiting Surgery

GP review every 4–8 weeks; monitor for neurological deterioration; activity restriction (avoid contact sport, falls prevention); manage associated pain and spasticity symptomatically; do not delay surgical referral.

Post-operative (0–6 months)

Wound review; medication management; early physiotherapy referral for gait and fine motor rehabilitation; neurological assessment — report any new symptoms to surgeon; imaging at specialist direction.

Long-term Post-operative

Annual GP neurological review; monitor for adjacent segment disease (new radiculopathy or myelopathic features above/below fusion level); long-term physiotherapy for ongoing rehabilitation; falls prevention.

References and Guidelines

Fehlings MG et al. — Degenerative Cervical Myelopathy: A Review of the Disease Spectrum, Diagnoses, and Management Strategies; Neurosurgery 2021
Nouri A et al. — Degenerative Cervical Myelopathy: Epidemiology, Genetics and Pathogenesis; Spine 2015
Tetreault L et al. — Degenerative Cervical Myelopathy: A Spectrum of Related Disorders Affecting the Aging Spine; Neurosurgery 2015
Kato S et al. — Surgical management of degenerative cervical myelopathy: a systematic review; Global Spine J 2021
Wilson JR et al. — Defining the Appropriate Threshold for Surgical Intervention in Patients With Mild Degenerative Cervical Myelopathy; Neurosurgery 2020
Matz PG et al. — The natural history of cervical spondylotic myelopathy; J Neurosurg Spine 2009
Spine Surgery Society of Australia and New Zealand — Clinical guidelines for the management of degenerative cervical spine disease
Royal Australian College of Surgeons — Cervical myelopathy: indications for surgery